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Background: Several studies have emphasized the importance of the maintenance of bone health in a
comprehensive cancer care. However, no survey about approach to bone metastasis care is currently
available. The ZeTa study provides a picture of the Italian oncologists’ therapeutics habits in this area, in
a real clinical-practice scenario.
Design: This study was based on online questionnaire-based interviews to Italian oncologists that
included 145 questions. The aim was to collect information on the treatment of bone metastasis, the
current use of bisphosphonates, the awareness of guidelines and the concerns about ONJ, the use of
vitamin D supplementation.
Results: 445 oncologists were contacted, 283 agreed to participate. The results show that the current
management of bone metastasis is still sub-optimal, as the recommendations from current clinical
guidelines are not completely followed by all specialists.
Conclusions: This survey highlights the urgent need to improve management of bone metastasis in
cancer patients.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Several types of cancers, including those originating in the breast,
prostate, and lung, have a propensity to metastasize to the bones
[1,2]. Bone metastases severely impair skeletal metabolism, and
result in important clinical sequelae, such as excruciating chronic
bone pain and the so-called skeletal-related events (SREs), such as
pathologic fracture, spinal-cord compression, surgery to bone, radio-
therapy to bone, hypercalcemia with a dramatic reduction in quality
of life and increased risk of death of the affected patients [2].
Moreover, different systemic oncologic treatments, including
chemotherapy and endocrine therapy, further accelerate the
natural process of bone loss, a phenomenon known as cancer
treatment-induced bone loss (CITBL) [3,4]. This event, which is
associated with an increased risk of fractures and worsening of
prognosis, is observed for instance in breast cancer patients
undergoing treatment with aromatase inhibitors, or in men with
prostate cancer on androgen deprivation therapy [3,4].. This is an open access article un
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appendix.Bone health, which includes the management of bonemetastases
and the treatment of CITBL, is a major concern in cancer patients.
Several international guidelines/recommendations of major scienti-
ﬁc societies (e.g. the American Society of Clinical Oncology [ASCO]
and the National Comprehensive Cancer Network [NCCN]) have
emphasized the importance of the maintenance of bone health, as
an important component of comprehensive cancer care [5–10]. In
particular, the use of bisphosphonates (BPs), potent inhibitors of
bone resorption, to prevent, reduce, and delay cancer-related SREs
and CITBL in cancer patients is supported by a general consensus
[5–12], even if BP treatment is potentially associated with the onset
of osteonecrosis of the jaw (ONJ) [5–10].
Although several guidelines for the treatment and management
of cancer patients are now available, there is the perception of a
wide gap between recommendations and actual clinical practice in
Western Countries, including Italy [13–15]. However, to our knowl-
edge, no survey of the oncologists’ approach to bone metastasis care
in cancer patients has been conducted to date, while it appears
highly advocated. In addition, it has been suggested that further
education of healthcare professionals is necessary to improve the
awareness of the importance of bone health management in cancer
patients, and to optimize speciﬁc medical therapy in this setting
[16,17]. The introduction of new therapies, such as BP treatment,
and the publication of new evidence in this ﬁeld may result inder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Proportion of patients receiving a treatment for bone metastasis, according to the









Any treatment (%) 85 82 90 78
D. Santini et al. / Journal of Bone Oncology 1 (2012) 35–3936measures to increase the level of education and training of oncol-
ogists and therefore improve the standard of care. This goal can be
achieved, in our opinion, only if a clear picture of real clinical
practice becomes available.
The aim of the ZeTa (ZomEta TAsk force) study is to provide a
picture of the Italian oncologists’ therapeutic habits in the care of
bone metastasis, in real-life clinical practice.Radiotherapy (%) 37 43 40 42
Radio-metabolic
therapy (%)
2 1 7 2
Surgery (%) 3 2 2 2
Chemo/hormonal
therapy (%)
63 57 63 64
Interventional
radiology (%)
6 5 3 4
Bisphosphonates (%) 70 62 69 702. Methods
This Italian study was based on online questionnaire-based
interviews with Italian oncologists recruited via telephone.
The questionnaire was developed with the cooperation of a
selected group of Italian oncologists, who are all experts in the ﬁeld
of bone health. The questionnaire included 145 questions (39 single-
choice questions, 15 multiple-choice questions, 18 ﬁve-point ordinal
scales, 34 ten-point ordinal scales, 35 numeric questions, and
4 open-ended), and was designed to collect information on the
responding oncologist and his/her institution, the treatment of bone
metastasis adopted in clinical practice, the current use of BPs in this
setting, the awareness of guidelines and the concerns about ONJ, the
use of vitamin D supplementation, and the foreseen developments
of BPs treatment. The questionnaire was tested by the selected
group of oncologists and some co-workers of theirs before the
recruitment of participating clinicians.
The recruitment of the oncologists was conducted by GfK
Eurisko, the leading market research organization operating in
Italy (http://www.gfk.com/gfk-eurisko/index.en.html).
Four types of cancer were considered in this analysis (breast,
lung, prostate and genito-urinary): therefore, it was decided to
contact more than one oncologist per center, in order to collect
the widest possible experience. Each oncologist was requested to
reply to the questions regarding the type of cancer in which he or
she had the highest level of experience; all participants were also
free to address the questions regarding other types of cancer.
Respondents did not receive monetary compensation for com-
pleting the questionnaire.
2.1. Statistical analysis
Descriptive statistics were calculated on the total sample. The
conﬁdence level used in the calculation of signiﬁcance tests for all
data is 95%. The maximum sampling error of population para-
meters’ esteems—at the 95% level of conﬁdence—is 5.5%. Missing
replies were not considered for this analysis.3. Results
3.1. Participating oncologists and related institutions
In total, 170 centers were selected for inclusion in this survey,
out of 350 Italian oncology centers (Source: Libro Bianco AIOM,
3rd edition; www.aiom.it). The centers were selected in order to
be representative of all Italian regions; the centers were also
stratiﬁed in terms of number of beds.
In total, 445 oncologists were contacted, and 283 agreed to
participate (response rate: 63.6%; mean number of oncologists
per center: 1.67).
The majority of participating oncologists belonged to non-uni-
versity hospitals (N¼125; 44%), followed by those afﬁliated to
university hospitals (N¼59; 21%), or those working in an ASL
(Azienda Sanitaria Locale; a local service of healthcare) [N¼50;
18%]. Most oncologists were males (N¼173; 61%). No statistically
signiﬁcant difference in terms of oncologists’ gender was observed,either in relationship to the number of hospital beds or the Italian
geographical macro-area. Their mean age was 4678 years, but
about half of the sample was r45 years old (N¼136; 48%). Despite
the relatively young age of the participating oncologists, most of
them had 410 years’ experience in oncology practice (N¼181;
64%; mean 1678 years). Most oncologists (N¼184, 65%) answered
all sections of the questionnaire (breast, lung, prostate and genito-
urinary cancer), 11% answered three sections, 9% two sections, and
15% one section, on the basis of their experience in different types of
cancer.
3.2. Treatment of bone metastasis
Bone metastases are treated in the vast majority of patients,
mostly with BPs; however, about 15–20% of subjects, depending
upon the particular type of primary tumor, remain untreated for
their entire history of bone metastasis (Table 1). About 70% of
patients receive BP treatment, with the exception of subjects with
lung cancer (62%). Overall, radiotherapy is used in about 40% of
patients and chemo/hormonal therapy speciﬁcally designed for
the treatment of bone metastases in about 60% of patients.
The decision to treat bone metastasis is made, in most cases,
by consensus which includes other oncologists (32%) or other
specialists in different ﬁelds (42%). The decision to treat bone
metastasis is mainly made due to the presence of symptomatic
disease (considered a very relevant factor by 232 oncologists;
82%), the metastatic site (N¼164; 58%), and the potential risk of
SREs (N¼156; 55%). However, 232 oncologists (82%) stated that
they sometimes decide not to treat bone metastasis, because of
short life expectancy of the patient (62% of those declaring this
decision), low performance status (55%) or asymptomatic metas-
tasis (52%).
3.3. Risk of skeletal-related event (SRE) development
About 50% of Italian oncologists think that the median time to
ﬁrst SRE from the diagnosis of bone metastasis, independent of
the type of primary tumor, is more than 1 year. The risk of the
onset of SREs is mainly considered dependent upon the meta-
static site and the nature of the metastases (osteolytic vs.
osteoblastic vs. mixed) (Table 2). The majority of the clinicians
stated that the occurrence of an SRE is an important predictor of
the subsequent development of other SREs (N¼246; 87%) and is
associated with impairment of quality of life (N¼277; 98%), while
less consensus exists about the association between SREs and an
increased risk of death (N¼204; 72%). The rate of bone turnover
(assessed with bone turnover markers) was considered a pre-
dictor of SRE by only 10% of oncologists. Furthermore, in clinical
practice, only 8% of oncologists evaluate the markers of bone
turnover in order to predict the risk of SRE.
D. Santini et al. / Journal of Bone Oncology 1 (2012) 35–39 373.4. Treatment with bisposphonates (BPs)
In total, 170 oncologists (60%) prescribe BPs for the treatment
of bone metastasis independent of the evaluation of the risk of
SREs. This treatment is mainly intended to increase bone mass,
reduce the risk of fractures and to prevent the onset of SREs
(Fig. 1). About 60% believe that BPs may exert anticancer effects inTable 2
Factors contributing to the risk of skeletal-related events (SREs), according to the
oncologists participating to the survey (N¼283). Multiple choices were allowed.
Risk factor for SRE Percentage of oncologists
Metastatic site 75
Nature of the metastasis 70
Previous SRE 54
Extension of bone metastasis 50
Number of bone metastases 19
Time to onset/diagnosis of metastasis 12
Bone turnover 7
Fig. 1. Reasons for prescribing a treatment of bone metastasis with bisphosphonates, a
were allowed.
Fig. 2. Reasons for the interruption of bisphosphonate treatment before 24 months ac
were allowed.patients, and 28% think that this potential activity may result, in a
metastatic setting, in a signiﬁcant increase in survival. Zoledronic
acid appears to be the BP of choice for the therapy of bone
metastasis, as it is prescribed to about 80% of patients, regardless
of the cancer type.
BP treatment is usually started at the ﬁrst diagnosis of bone
metastasis, independent of the presence of pain (N¼212; 75%);
however, some clinicians normally prescribe a BP only if the
patient carries a high risk of SREs (N¼48; 17%) or after the onset
of pain (N¼20; 7%).
BP treatment, is suspended within 24 months of its initiation
according to 78% of oncologists (N¼221), is continued until disease
progression by 13% of the participants (N¼37), and is continued for
the entire natural history of disease by 9% (N¼25). The reasons for
treatment interruption before 24 months are, in most cases, because
of progression of bone disease (40% of clinicians interrupt BP
treatment before 24 months), occurrence of ONJ or SRE (19% each),
or worsening of pain (18%) (Fig. 2). Reasons for prolonging BP
treatment beyond this period are shown in Fig. 3. In total, 56% of
oncologists who prolong BP treatment longer than 24 months reduceccording to the oncologists participating to the survey (N¼283). Multiple choices
cording to the oncologists participating to the survey (N¼283). Multiple choices
Fig. 3. Reasons for the decision to prolong the treatment of bone metastasis beyond a 2-year period.
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modify the therapeutic schedule (6% prescribe a switch to another
BP). In most cases, the decision to prolong BP treatment beyond
2 years is taken in order to limit the risk of SRE (60%), to provide pain
relief (58%), to treat an SRE already present (54%) or because the
patient’s life expectancy is long (53%). In total, 81% of the oncologists
consider that the efﬁcacy of BP treatment does not decrease if the
schedule of administration is changed.
3.5. Safety perceptions and evaluation of the risk of osteonecrosis of
the jaw
The reduction of ONJ incidence due to the implementation of
dental hygiene protocols has contributed to less concern about
this condition by the majority of oncologists (N¼170; 60%);
however, a minority of clinicians (N¼20; 7%) stated that they
are more worried by ONJ than in the past.
Preventive measures (clinical, radiographic or dental evalua-
tion) are usually adopted before the initiation of BP treatment by
the vast majority of oncologists (N¼269 (95%): odontoiatric
assessment 91%; orthopantomography 82%; clinical evaluation
36%; N¼14, 5% of oncologists usually do not use preventive
measures before the start of treatment with BP ); however, these
measures are applied in all patients by only 66% of clinicians
(N¼187), whereas 29% (N¼82) prescribe these measures only in
patients at risk of ONJ. The same measures (odontoiatric assess-
ment, orthopantomography, clinical evaluation) are taken during
BP treatment by the majority of oncologists (90%), but only by
43% routinely in all patients.
3.6. Awareness of guidelines
In total, 62 oncologists (22%) declared not to be aware of any
guidelines, either national or international, for the speciﬁc treat-
ment of bone metastasis. Among those who stated their aware-
ness of one or more guideline, the AIOM (Associazione Italiana di
Oncologia Medica, Italian Association for Medical Oncology) guide-
lines [8] were the most well-known (79%), followed by those
issued by ASCO [9] (26%) and NCCN [5] (18%). In total, 86% of
interviewed oncologists consider the available guidelines as very
important for clinical practice.4. Discussion
The results of this large survey, conducted in 170 oncology
centers representative of all regions and clinical institutions in
Italy, suggest that the current management of bone metastasis in
cancer patients is still suboptimal. The recommendations from
current clinical guidelines issued by Italian (AIOM) [8] and
international (NCCN, ASCO, ESMO) [5,9,10] scientiﬁc societies
are not completely followed by all specialists. It must be recog-
nized that, like all observational surveys, the results of this study
are likely to be an overestimation of actual clinical practice, and it
cannot be ruled out that the understanding of each question may
be different among participating clinicians. However, the ques-
tionnaire was tested by a group of experts before initiating the
study, in order to limit this potential bias. In addition, the number
of participating oncologists was high (approximately 10–15% of
all Italian oncologists) and the participating clinicians had several
years of experience in oncology practice; in our opinion, these
factors could strengthen the validity of the results in reﬂecting
current clinical practice.
To our knowledge, this is the ﬁrst survey to speciﬁcally assess,
in daily clinical practice, the management of bone metastasis and,
in general, the perception of bone healthcare in Italy. However,
the ﬁndings of this analysis are in overall agreement with those of
previous studies, some referring to the Italian situation, in other
ﬁelds of cancer treatment, which have highlighted the wide gap
between guideline recommendations and clinical practice in the
oncology and bone health setting [13–17]. In all of these studies,
the level of care was suboptimal, and it was generally concluded
that, although the education of oncologists and healthcare provi-
ders is improving, further procedures and implementation of
educational programs to optimize their level of attention and
awareness are required [17].
A detailed summary of the current recommendations for the
management of bone metastasis in cancer patients is beyond the
scope of the present publication. However, we believe some critical
points deserve mentioning. For instance, while BPs, and in particular
zoledronic acid, are prescribed by the majority of oncologists, it
must be recognized that the main objectives of this therapy are, in
the participants’ opinion, of a palliative nature (e.g. pain relief)
rather than curative (e.g. reduction of risk of death related to SRE).
Moreover, about half of the participating oncologists may decide not
D. Santini et al. / Journal of Bone Oncology 1 (2012) 35–39 39to treat asymptomatic bone metastases: current consensus recom-
mends that BP treatment should be initiated regardless of the
presence of symptomatic metastases and the development of SRE
[6,8,18]. About 30% of participants do not support the association
between SREs and the increase in the risk of death, despite it being
well-documented in the medical literature [19,20]. Moreover, only a
minor proportion of specialists consider bone turnover (measured
with bone turnover markers such as urinary NTX or serum CTX) as a
predictive factor for the appearance of SRE, despite different
suggestions published in literature [1].
Some gaps between the actual prescribing attitudes of oncol-
ogy specialists and current guidelines about BP treatment in
oncology patients have also been highlighted by the present
survey. About one out of four of the involved oncologists does
not start BP treatment at the diagnosis of bone metastasis,
contrary to current international recommendations [5–10]. Addi-
tionally, about 40% of oncologists interrupt zoledronic acid
therapy when skeletal disease progresses, pain develops, or an
SRE occurs, rather than continuing the same bisphosphonate as
suggested by guidelines [6,8].
Interestingly, for about 40% of oncologists, ONJ still represents
a concern in patients during BP treatment, despite current guide-
lines agreeing on the high efﬁcacy of preventive measures, which
should be implemented in all patients assigned to BP therapy
[5–10]. Finally, the most alarming result was that about 20% of
oncologists appear not to be aware of or follow any guidelines for
the maintenance of bone health in their clinical practice.
Taken together, we believe that the results of this survey
highlight an urgent need for further education of Italian oncolo-
gists in order to improve their awareness of the importance of
bone health and the management of skeletal problems in cancer
patients; for example, improving the educational programs on
bone metastasis management in cancer patient during medical
degree courses or during post-degree training, in cooperation
with national and international scientiﬁc societies.Funding
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